Oxurion NV will file for bankruptcy following KALAHARI data release
In the clinical trial, Oxurion’s novel PKal Inhibitor, THR-149, did not meet its primary endpoint.
AAO 2023: Retinal visualization and patients who've had small aperture IOL implantation
Mark Blecher, MD, spoke with the Ophthalmology Times team about his poster addressing retinal visualization and patients who've had small aperture IOL implantation at this year's American Academy of Ophthalmology meeting.
AAO 2023: The GALE study for geographic atrophy management
Charles Wykoff, MD, PhD, spoke with the Ophthalmology Times team about the GALE study looking at pegcetacoplan for the management of geographic atrophy at this year's American Academy of Ophthalmology meeting.
Medicines and Healthcare products Regulatory Agency (MHRA) issues UK marketing approval for Biocon Biologics biosimilar aflibercept (YESAFILI)
Biocon’s YESAFILI is intended for treatment of a number of ocular conditions, including neovascular AMD, visual impairment due to myopic choroidal neovascularisation, visual impairment due to DME and visual impairment due to macular edema secondary to retinal vein occlusion.
EMA recommends approval of high-dose intravitreal aflibercept (Eylea®) 8mg for nAMD and macular edema
The endorsement follows FDA approval in the United States this summer.
AAO 2023: Blindness and vision loss in the United States: Do women bear a greater burden?
Mary Elizabeth Hartnett, MD, FACS, discussed the impact of blindness and vision loss on women in the United States.
Bausch + Lomb announces launch of Pure‐line gases for retina surgeons ahead of EURETINA annual meeting
The new range of pure and premixed gases are intended for medium-term use in retinal surgery.
EURETINA 2023: Ali Erginay, MD, discusses advancements in ultra-widefield imaging
Ali Erginay, MD, of Lariboisière Hospital in Paris, France, discusses his EURETINA presentation, "Introducing optomap® Ultra-widefield Colour Red-Green-Blue Multimodal Imaging."
EURETINA 2023: Varun Chaudhary, MD, discusses posturing after macular hole surgery
Our team spoke to Varun Chaudhary, MD, about his EURETINA presentation, titled "Systematic Review and Metanalysis in Macular Hole RCTs – Posturing after Macular Hole Surgery."
Syncona announces Novartis will discontinue development of GT005 for geographic atrophy
Novartis acquired Gyroscope Holdings Limited from Syncona in February 2022.
Orbis and Heidelberg Engineering announce new partnership
The non-profit will partner with the imaging company to prevent blindness and fund new retinoblastoma research.
EMA approves Clinical Trial Application for retinitis pigmentosa therapy from ViGeneron
European Medicines Agency issued approval for a Clinical Trial Application of its new gene therapy, VG901, which uses an adeno-associated virus vector to treat CNGA1-associated retinitis pigmentosa.
Sandoz shares positive results for biosimilar aflibercept in MYLIGHT Phase 3 study
The study met its primary efficacy endpoint for the neovascular age-related macular degeneration (nAMD) treatment.
Tenpoint Therapeutics receives $70 million Series A financing
Tenpoint’s aim is to reverse vision loss by generating specialized ocular cell types, both ex vivo and in vivo.
Clinical Trials at the Summit 2023: Update on avacincaptad pegol for GA
Margaret Chang, MD, MS, spoke with Modern Retina to give an update on avacincaptad pegol for geographic atrophy.
2 Clarke Drive Cranbury, NJ 08512